| News Updates |
 |
Peer-reviewed data shows remdesivir for COVID-19 improves time to recovery
NIH | May 22, 2020
|
|
New COVID-19 CDC Resources on PrEP and Liver Disease
HIV.gov | May 21, 2020
|
|
NIH Study: Long-Acting Injectable Drug Prevents HIV Among Men Who Have Sex with Men, and Transgender Women
HIV.gov | May 18, 2020
|
|
HIV-1 Salvage Therapy Can Omit NRTIs and Remain Efficacious and Safe
Infectious Disease Advisor | May 7, 2020
|
|
FDA authorizing the emergency use of remdesivir for treatment of COVID-19 |
|
Updated 2020 National AIDS Drug Assistance Program (ADAP) Formulary Database
NASTAD | April 2020
|
|
NIH-funded research leads to pediatric labeling updates for doxycycline, clindamycin and caffeine citrate
NIH | April 2, 2020
|
|
Virological and immunological impact of integrase inhibitor-based regimens initiated during primary HIV-1 infection
NCBI | March 2020
|
|
ADAP Advocacy Association Applauds Pharmaceutical Industry Efforts on Protecting the Drug Supply Chain during the Coronavirus Pandemic
ADAP Advocacy Association | March 26, 2020
|
|
ViiV Healthcare on Friday announced that Health Canada has approved Cabenuva (cabotegravir and rilpivirine)
The Pharma Letter | March 21, 2020
|
|
EPCLUSA: Labeling Updates for Pediatric Patients
FDA | March 19, 2019
|
|
Newer anti-HIV drugs safest, most effective during pregnancy
NIH | March 11, 2020
|
|
METABOLIC COMPLICATIONS OF HIV AND ITS THERAPIES
CROI 2020 March 11
|
|
New Data on Gilead’s Biktarvy® Presented at CROI 2020, Including Data in Black Americans and Older Adults
Gilead Sciences, Inc | March 9, 2020
|
|
ViiV Healthcare presents positive 48-week data from phase III study showing every-two-month regimen of investigational long-acting, injectable cabotegravir and rilpivirine has similar efficacy to once-monthly dosing
ViiV | March 9, 2020
|
|
Testosterone Use Tied to Signals of Atherosclerosis Progression in Men With HIV
CROI 2020, March 8-11, 2020, Boston
|
|
Initial Weight, Low CD4/CD8, Low Activity Drive Weight Gains After InSTI Switch
CROI 2020, March 8-11, 2020, Boston
|
|
F/TAF and F/TDF Efficacy and Safety as PrEP for 96 Weeks
CROI 2020, March 8-11, 2020, Boston
|
|
Cost Analysis Questions Value of F/TAF vs Generic F/TDF for PrEP
CROI 2020, March 8-11, 2020, Boston
|
|
Maraviroc Does Not Demonstrate Clinical Benefit in Advanced HIV
Infectious Disease Advisor | March 5, 2020
|
|
SYMTUZA: Pediatric Labeling Updates
FDA | March 4, 2020
|
|
Monthly Injectable Antiretroviral Therapy — Version 1.0 of a New Treatment Approach
The New England Journal of Medicine | March 4, 2020
|
|
Gilead Presents Data on Investigational HIV-1 Capsid Inhibitor GS-6207 as a Potential Component of Long-Acting HIV Therapy
Gilead Sciences, Inc | November 8, 2019
|
|
A Secure Drug Supply Chain is the Best Anti-Counterfeiting Technology We Have
ADAP Advocacy Association | February 27, 2020
|
|
Rockefeller grants commercial license for the development of new HIV drugs
Rockerfeller | February 26, 2020
|
|
The effect of tenofovir disoproxil fumarate on bone mineral density: a systematic review and meta-analysis
Antivir Ther. 2020 Feb 20. doi: 10.3851/IMP3346.
|
|
Adding maraviroc to standard treatment for advanced HIV does not improve outcomes
Healio | February 10, 2020
|
|
Just one dose of HPV vaccine may confer durable cervical cancer protection
Healio | February 10, 2020
|
|
AbbVie Receives Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) to Shorten Treatment Duration to Eight Weeks in Genotype 3, Treatment-Naïve Patients with Chronic Hepatitis C and Compensated Cirrhosis
abbvie | January 31, 2020
|
|
VEMLIDY: Labeling Updates
FDA | February 4, 2020
|
|
Opioid Prescribing Behaviors — Prescription Behavior Surveillance System, 11 States, 2010–2016
CDC | January 31, 2020
|
|
A Study of Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) to Maintain Viral Suppression in Adults Living with HIV-1: A Multicenter Trial of the AIDS Clinical Trials Group (ACTG)
NATAP | January 2020
|
|
ViiV Healthcare submits regulatory application to the European Medicines Agency for fostemsavir, an investigational, first-in-class attachment inhibitor for the treatment of HIV in adults with few treatment options available
ViiV Healthcare | London, 10 January 2020
|
|
Gilead Sciences Licenses Portfolio of HIV Antibodies From The Rockefeller University
FOSTER CITY, Calif.--(BUSINESS WIRE)--Jan. 9, 2020
|
|
FDA Programs to Register HIV Drugs for Use in Resource-Constrained Settings
Infectious Disease Advisor | January 3, 2020
|
|
Following backlash, Facebook disables misleading HIV medication ads
Dec. 30, 2019, 3:44 PM EST
|
|
Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in a Rapid Initiation Model of Care for HIV-1 Infection: Primary Analysis of the DIAMOND Study
Clinical Infectious Diseases 27 December 2019
|
|
What's New in the Guidelines?
aidsinfo | December 2019
|
|
ViiV Healthcare receives complete response letter from US FDA for use of investigational cabotegravir and rilpivirine long-acting regimen in the treatment of HIV
ViiV Healthcare | December 21, 2019
|
|
Prescribing practices for pregnant women with HIV not aligned with guidelines
Healio | December 18, 2019
|
|
Facebook ads are spreading lies about anti-HIV drug PrEP. The company won't act
The Guardian | December 14, 2019
|
|
Cost prevents 7% of people will HIV from adhering to medication
Healio | December 12, 2019
|
|
ViiV Healthcare submits New Drug Application to the FDA for fostemsavir, an investigational, first-in-class attachment inhibitor for the treatment of HIV in adults with few treatment options available
Viiv | December 5, 2019
|
|
HARVONI, EPCLUSA, and VOSEVI Labeling updates: HCV-infected adults with severe renal impairment
FDA | November 18, 2019
|
|
CDC Antibiotic Resistance: New Threats Report |
|
Understanding the Medicaid Prescription Drug Rebate Program – Kaiser Family Foundation
KFF | November 12, 2019
|
|
Untangling the Trump administration's lawsuit over an HIV prevention drug
Science Magazine | November 8, 2019
|
|
Facts About Gilead’s PrEP Medications Donation to Help Support Ending the HIV Epidemic Efforts
NATAP | November 4, 2019 at 12:01:02 PM EST
|
|
Gilead Perspective on HHS Lawsuit |
|
The ADVANCE clinical trial: changes from baseline to week 96 in DXA-assessed body composition in TAF/FTC+DTG compared to TDF/FTC+DTG, and TDF/FTC/EFV
17th European AIDS Conference, November 6-9, 2019, Basel
|
|
Integrase Inhibitors Tied to Weight Gain, Hepatic Steatosis in Longitudinal Cohort
17th European AIDS Conference, November 6-9, 2019, Basel
|
|
INI Resistance Remains Rare in INI-Naive--Initial CD4, Viral Load Predict Failure
17th European AIDS Conference, November 6-9, 2019, Basel
|
|
Switch From TDF to TAF in HIV/HBV+ Maintains Viral Control, Helps Kidneys
17th European AIDS Conference, November 6-9, 2019, Basel
|
|
DTG Easily Most Popular INI Across Europe, With Lowest Quitting Rate
17th European AIDS Conference, November 6-9, 2019, Basel
|
|
Gilead Presents Data on Investigational HIV-1 Capsid Inhibitor GS-6207 as a Potential Component of Long-Acting HIV Therapy
Gilead | November 8, 2019
|
|
BARACLUDE: Updates to Adverse Reactions from Long-Term Observational Study
FDA | November 8, 2019
|
|
Label updates to efavirenz containing products
FDA | October 30, 2019
|
|
Hepatitis C Treatments Are Safe and Effective for Seniors
POZ | October 28, 2019
|
|
Dolutegravir and risk of neural tube defects: Labeling Updates
FDA | October 25, 2019
|
|
Gilead Announced It Will Donate 2.4 Million Bottles of Truvada for PrEP. Here's How It Will Work
The Body Pro | October 16, 2019
|
|
Rapid ART Initiation: A New Model Presents Unique Opportunities and Challenges
Contagionlive.com | October 11, 2019
|
|
The 8th World Workshop on Oral Health and Disease in AIDS
BRITISH DENTAL JOURNAL | VOLUME 227 NO. 7 | October 11 2019
Photos courtesy of Dr. David Croser
|
|
IDWeek 2019: ViiV Healthcare to present 20 abstracts from its innovative R&D portfolio with focus on 2-drug and long-acting regimens and mental health impact of HIV
ViiV Healthcare | October 2, 2019
|
|
MAVYRET: new dosage regimen and labeling updates
FDA | October 1, 2019
|
|
FDA approves new HIV treatment (Long-Acting Ibalizumab) for patients who have limited treatment options
NATAP | September 26, 2019
|
|
Merck’s PIFELTRO™ (doravirine) and DELSTRIGO™ (doravirine/lamivudine/tenofovir disoproxil fumarate) Receive US FDA Approval for Use in Appropriate Adults Living with HIV-1 Who Are Virologically Suppressed
Business Wire | September 20, 2019
|
|
Theratechnologies Reaches Agreement With AIDS Drug Assistance Program (ADAP) for New EGRIFTA SV
Yahoo Finance | September 19, 2019
|
|
FDA warns patients and health care professionals about rare instances of serious liver injury or failure with certain hepatitis C treatments in some patients with advanced liver disease
FDA | August 28, 2019
|
|
ViiV Healthcare reports positive phase III study results of investigational, long-acting, injectable HIV-treatment regimen administered every two months
GSK | August 22, 2019
|
|
Extensive Drug Resistance Has Become Rare Among People With HIV
POZ | August 19, 2019
|
|
FDA panel backs Gilead's HIV prevention drug for certain population
Reuters | August 7, 2019
|
|
BIKTARVY: recent changes to labeling
FDA | August 6, 2019
|
|
ViiV Healthcare Submits Regulatory Application to European Medicines Agency for Investigational ...
Yahoo Finance | July 29, 2019
|
|
WHO Recommends Antiretroviral Drug Dolutegravir As Preferred HIV Treatment, Including For ...
Kaiser Family Foundation | July 23, 2019
|
|
Folic acid reduces risk of neural tube defects linked to HIV drug dolutegravir
EurekAlert | July 23, 2019
|
|
Efficacy and safety of dolutegravir–rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies
The Lancet | July 12, 2019
|
|
Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV
aidsinfo | July 10, 2019
|
|
Merck Highlights Commitment to HIV Research with Presentations for Investigational Anti-HIV Agent MK-8591 at IAS 2019
BioSpace | July 10, 2019
|
|
ViiV Healthcare announces phase III study meets primary endpoint, demonstrating the ability to control HIV-1 with a 2-drug regimen of dolutegravir plus lamivudine in virally suppressed patients switching from a TAF-containing, 3-drug regimen
ViiV Healthcare | July 10, 2019
|
|
GSK's Dovato suppresses AIDS virus at same levels of three-drug regimen
Reuters | July 10, 2019
|
|
Gilead and Lyndra Team Up to Develop Long-Acting HIV Therapies
BioSpace | July 9, 2019
|
|
ViiV Healthcare announces start of first-ever study to identify and evaluate approaches to implementing its once-monthly injectable HIV treatment in clinical practice
ViiV Healthcare | July 8, 2019
|
|
FDA: HIV Email Updates | July 1, 2019
|
|
Long-Acting Antiretrovirals for Treatment
NASTAD | June 26, 2019
|
|
HIV Updates: BIKTARVY label revisions |
|
HIV drug cabotegravir not associated with weight gain
Healio | June 8, 2019
|
|
AIDS groups criticize Express Scripts for excluding several HIV medicines
STAT | June 6, 2019
|
|
National Ryan White HIV/AIDS Program (RWHAP) Part B and AIDS Drug Assistance Program (ADAP) Monitoring Project: 2019 Annual Report
NASTAD | June 6, 2019
|
|
Other than dolutegravir, no antiretroviral interactions with valproic acid in 134 people
20th International Workshop on Clinical Pharmacology of HIV, Hepatitis & Other Antiviral Drugs. May 14-16, 2019. Noordwijk, the Netherlands |
|
Phase 1 results show safety and once-daily potential of new HIV maturation inhibitor
20th International Workshop on Clinical Pharmacology of HIV, Hepatitis & Other Antiviral Drugs. May 14-16, 2019. Noordwijk, the Netherlands
|
|
Management of antiretrovirals in Seniors - The importance of assisted treatment for adherence to treatment
20th International Workshop on Clinical Pharmacology of HIV, Hepatitis & Other Antiviral Drugs. May 14-16, 2019. Noordwijk, the Netherlands
|
|
One third of French HIV group uses illicit drugs, often risking antiretroviral interactions
20th International Workshop on Clinical Pharmacology of HIV, Hepatitis & Other Antiviral Drugs. May 14-16, 2019. Noordwijk, the Netherlands
|
|
Baseline genotype testing at HIV diagnosis not cost-effective
Healio | May 13, 2019
|
|
Gilead to Donate Up to 2.4M Bottles of HIV Prevention Pills Each Year in the U.S.
POZ | May 10, 2019
|
|
NIH Trial Evaluates Long-acting HIV Medication Unable to Adhere to Strict Daily Regimens
NIH | May 9, 2019
|
|
The Lancet | May 5, 2019
|
|
ViiV Healthcare seeks FDA approval for long-term injectable HIV treatment
WRAL Tech Wire | April 29, 2019
|
|
MSM at Highest Risk for HIV Acquisition Express Greatest Interest and Preference for Injectable Antiretroviral PrEP Compared to Daily, Oral Medication
AIDS Behav. 2018 Apr;22(4):1158-1164. doi: 10.1007/s10461-017-1972-6
|
|
Updates New ARTs/ New ART Data - CROI including Bictegravir, Dolutegravir+Rilpivirine, Dolutegravir+3TC, Doravirine; Fostemsavir & MK-8591
NATAP | April 10, 2019
|
|
NATAP: HIV-Drug Resistance Testing/DHHS Guidelines
Last Updated: October 25, 2018
|
|
ViiV Healthcare Announces CHMP Positive Opinion for DOVATO® (DOLUTEGRAVIR/LAMIVUDINE) as a Once-Daily, Single-Pill, Two-Drug Reimen for the Treatment of HIV Infection
ViiV | April 26, 2019
|
|
New Rule at Centers for Medicare and Medicaid Helps Lower Costs of Meds
POZ | April 23, 2019
Special thanks to The AIDS Institute for leading the charge on this important issue
|
|
Expanded Access - Pre-Approval Access to Rilpivirine Long Acting (RPV LA) Injectable Suspension for the Treatment of a Participant With Human Immunodeficiency Virus (HIV)-1 Infection
NATAP | April 18, 2019
|
|
FDA Has Approved New Two-Drug Regimen to Treat People with HIV
Healthline | April 15, 2019
|
|
Janssen | April 11, 2019
|
|
FDA | April 8, 2019
|
|
Market Watch | Apr 9, 2019
|
|
Pharma giant profits from HIV treatment funded by taxpayers and patented by the government
Washington Post | March 26, 2019
|
|
Gilead's Asegua Therapeutics selected to partner with health department for hepatitis C drug subscription model
Gilead | March 26, 2019
|
|
Long-acting injectable treatment maintains viral suppression
aidsmap | March 8, 2019
|
|
Factors associated with therapeutic failure of 2-drug regimens, DAT’AIDS cohort: Two-antiretroviral maintenance failure--raltegravir regimens seem most vulnerable
Conference on Retroviruses and Opportunistic Infections (CROI), March 4-7, 2019, Seattle
|
|
Integrase inhibitor treatment leads to greater weight gain
aidsmap | March 7, 2019
|
|
ViiV Healthcare Presents Positive, 48-Week Data from Two Pivotal Phase III Studies Showing Long-Acting, Injectable Two-Drug Regimen of Cabotegravir and Rilpivirine Has Similar Efficacy to Daily, Three-Drug Oral Treatment in Adults Living with HIV-1 Infection
ViiV | March 7, 2019
|
|
HIV-1 escape in the central nervous system on elvitegravir-based antiretroviral therapy
AIDS: March 1, 2019
|
|
Gilead | February 11, 2019
|
|
Acyclovir labeling now includes details for treating premature infants infected with herpes virus
NIH | February 8, 2019
|
|
FDA Hepatitis Update- VEMLIDY labeling revised (renal information)
FDA | February 6, 2019
|
|
U.S. FDA Accepts sNDAs for PIFELTRO™ (doravirine) and DELSTRIGO™ (doravirine / lamivudine / tenofovir disoproxil fumarate)
Merck | January 22, 2019 |
|
Pharm To Exam Table – Candida glabrata Urinary Tract Infections
University of Nebraska Medical Center | December 21, 2018
Note from Dr. Reznik – This information is valuable for oral infections with Candida glabrata
|
|
HIV EMAIL UPDATES
FDA | December 11, 2018
|
|
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials
The Lancet | November 9, 2018
|
|
Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial
PLoS Med. 2018 Nov 8;15(11):e1002690. doi: 10.1371/journal.pmed.1002690. eCollection 2018 Nov
|
|
FDA HIV Update: GENVOYA, STRIBILD, and TYBOST Pregnancy Label
FDA | November 7, 2018
|
|
Novel antibiotic shows promise in treatment of uncomplicated gonorrhea
NIH | November 7, 2018
|
|
NASTAD Announces the Release of PrEPcost.org
NASTAD | November 6, 2018
|
|
Development of an End-user Informed Tenofovir Alafenamide (TAF) Implant for Long-acting (LA)-HIV Pre-exposure Prophylaxis (PrEP)
NATAP | November 6, 2018
|
|
Transgender women taking PrEP have lower levels of PrEP drugs, especially in rectal tissues, than ...
aidsmap | November 2018
|
|
Prolonged HIV suppression is possible using ibalizumab, analysis of highly drug-resistant patients ...
aidsmap | November 2, 2018
|
|
Dolutegravir or lower-dose efavirenz equally effective, but less resistance with dolutegravir
aidsmap | November 1, 2018
|
|
FDA HIV Update- ODEFSEY/COMPLERA: Pregnancy Label Updates
FDA | October 31, 2018
|
|
ViiV Healthcare reports positive 48-week results for second phase III study for novel, long-acting, injectable HIV-treatment regimen
HIV Drug Therapy, Glasgow 2018, October 28-31, 2018, Glasgow
|
|
Two Thirds Reach Sub-50 Viral Load Through 48 Weeks With Ibalizumab
HIV Drug Therapy, Glasgow 2018, October 28-31, 2018, Glasgow
|
|
Polypharmacy in One Third of Big HIV Cohort vs One Fifth of Non-HIV Group
HIV Drug Therapy, Glasgow 2018, October 28-31, 2018, Glasgow |
|
Good HIV Response Rate, Sustained Safety Through 96 Weeks With D/C/F/TAF
HIV Drug Therapy, Glasgow 2018, October 28-31, 2018, Glasgow |
|
Outcomes of Patients Not Achieving Primary Endpoint From an Ibalizumba Phase 3 Trial
HIV Drug Therapy, Glasgow 2018, October 28-31, 2018, Glasgow
|
|
Bictegravir/F/TAF Noninferior to DTG Plus F/TAF at 96 Weeks: No Resistance
HIV Drug Therapy, Glasgow 2018, October 28-31, 2018, Glasgow |
| |
|
